Journal
Blood Advances
Publication Date
9-12-2023
Volume
7
Issue
17
First Page
5038
Last Page
5046
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023010133
Rights and Permissions
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023 Sep 12;7(17):5038-5046. doi: 10.1182/bloodadvances.2023010133. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Epperla, Narendranath; Shea, Lauren; Bartlett, Nancy L; and et al., "Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: A multicenter cohort study." Blood Advances. 7, 17. 5038 - 5046. (2023).
https://digitalcommons.wustl.edu/oa_4/2199
Additional Links
Supplemental material is available for this article at publisher site.
